A Raptor with No Qualms About Eating Its Opponents Wins New Zealand’s Annual Bird Election 

A kārearea or New Zealand falcon is pictured in Fiordland National Park in New Zealand, on Jan. 4, 2011. (Craig McKenzie via AP)
A kārearea or New Zealand falcon is pictured in Fiordland National Park in New Zealand, on Jan. 4, 2011. (Craig McKenzie via AP)
TT

A Raptor with No Qualms About Eating Its Opponents Wins New Zealand’s Annual Bird Election 

A kārearea or New Zealand falcon is pictured in Fiordland National Park in New Zealand, on Jan. 4, 2011. (Craig McKenzie via AP)
A kārearea or New Zealand falcon is pictured in Fiordland National Park in New Zealand, on Jan. 4, 2011. (Craig McKenzie via AP)

New Zealand ’s annual bird election is contested by cheeky parrots, sweet songbirds and cute, puffball robins. This year’s winner was a mysterious falcon that wouldn’t think twice about eating them.

Kārearea, the Indigenous Māori name for the New Zealand falcon, was crowned Bird of the Year on Monday. But the annual poll, run by conservation group Forest & Bird, is no ordinary online vote.

The fiercely fought election sees volunteer (human) campaign managers apply to stump for their favorite bird. Feathers fly as avian enthusiasts seek to sway the public through meme battles, trash-talking poster campaigns and dance routines performed in bird costumes.

“Bird of the Year has grown from a simple email poll in 2005 to a hotly contested cultural moment,” said Forest & Bird Chief Executive Nicola Toki. “Behind the memes and mayhem is a serious message.”

The contest draws attention to New Zealand’s native bird species, with 80% designated as being in trouble to some degree. But it attracts passionate fandom because New Zealanders are bird-obsessed.

In a country with no native land mammals except for two species of bat, birds reign supreme. They appear in art, on jewelry, in schoolchildren’s songs, and in the name New Zealanders are known by abroad, “kiwis.”

Beloved birds include alpine parrots that harass tourists and pigeons which get so drunk on berries that they sometimes fall out of trees.

“This is not a land of lions, tigers and bears,” said Toki. “The birds here are weird and wonderful and not what you would expect to see perhaps in other countries.”

The first contest two decades ago attracted fewer than 900 votes. More than 75,000 people in the country of 5 million cast ballots this year.

It was the highest-ever voter turnout apart from an episode when Last Week Tonight host John Oliver volunteered as a campaign manager in 2023, prompting mostly joking accusations from New Zealanders of American interference. Perhaps inevitably, Oliver’s bird, the pūteketeke or Australasian crested grebe, won in a 290,000-vote landslide.

Other controversies have struck the poll. In 2021, there was mild uproar when a bat won the title, despite not being a bird.

The vote was ruffled by a foreign influence scandal in 2018 when self-styled comedians in Australia cast hundreds of fraudulent votes for a bird that shares its name with an Antipodean slang term for sex. Voters must now verify the email addresses used to cast their votes.

Forest & Bird said 87% of the votes in this year’s poll came from New Zealand. The falcon’s more than 14,500 votes appeared to have been won fair and square.

The majestic kārearea can fly at speeds of more than 200 km (124 miles) per hour and swoops to capture its prey, often smaller birds. The endemic species is threatened in New Zealand, vulnerable to electrocution on wires and loss of their forest habitats.

“They’re a mysterious bird and that’s partly because they’re cryptic, they’re often well-hidden,” said Phil Bradfield, a trustee of Kārearea Falcon Trust in Marlborough, on New Zealand’s South Island.

Official figures suggest between 5,000 and 8,000 New Zealand falcons remaining, although the true number is unknown. Bradfield said the “fast and sneaky and very special” raptor was a deserving Bird of the Year winner.

Other campaigns knew victory on Monday would take a miracle. Birds that are ugly — but not ugly enough to be funny — unknown or perceived as boring face an uphill slog.

That doesn’t deter bird lovers. The year 2025 was the first that all 73 bird competitors attracted campaign managers, with some electing to stump for contenders they knew would lose.

One was Marc Daalder whose scrappy, grassroots campaign for the tākapu, or Australasian gannet, drew 962 votes — about a 15th of the falcon’s.

“Running a campaign for one of the less popular birds is a more satisfying experience because you know the votes your bird received are a result of your hard work,” said Daalder, who is a (human) political journalist and three-time (bird) campaign manager.

Despite the near-record voter turnout, Toki from Forest & Bird said she feared New Zealanders would give up on some of the most threatened species as they grew more costly to protect, particularly from predators such as cats, rats and stoats.

“Successive governments in New Zealand have cumulatively reduced investment in conservation, which is the cornerstone of New Zealand’s economic prosperity,” she said, referring to tourism campaigns promoting the country’s scenic landscapes.

“People come here to see our native birds and the places they live in,” she said. “They’re not coming here to see shopping malls.”



Mexican Baby Monkey Finds Comfort in Plush Companion

A baby monkey named Yuji drinks milk while receiving care at a special care center at the zoo in Guadalajara, Mexico, Wednesday, April 15, 2026. (AP Photo/Refugio Ruiz)
A baby monkey named Yuji drinks milk while receiving care at a special care center at the zoo in Guadalajara, Mexico, Wednesday, April 15, 2026. (AP Photo/Refugio Ruiz)
TT

Mexican Baby Monkey Finds Comfort in Plush Companion

A baby monkey named Yuji drinks milk while receiving care at a special care center at the zoo in Guadalajara, Mexico, Wednesday, April 15, 2026. (AP Photo/Refugio Ruiz)
A baby monkey named Yuji drinks milk while receiving care at a special care center at the zoo in Guadalajara, Mexico, Wednesday, April 15, 2026. (AP Photo/Refugio Ruiz)

Yuji, a 6-week-old patas monkey in Mexico, wakes up every day clinging to a stuffed dog. More than a toy, this plush companion acts as a surrogate mom after the tiny primate was rejected by his own mother, Kamaria, a first-time parent unable to form a maternal bond.

Weighing a mere 673 grams (1.4 pounds), Yuji represents the most recent case of assisted rearing at the Guadalajara Zoo in western Mexico.

The story of Yuji has captured the attention of the Mexican public, drawing parallels to Punch, the Japanese macaque that went viral on social media after growing up clinging to a stuffed orangutan following his mother’s rejection, The Associated Press reported.

Unlike Punch, Yuji has not yet had physical contact with other members of his species; he spends most of his time inside a monkey crate at the Guadalajara Zoo’s Comprehensive Center for Animal Medicine and Welfare, CIMBA, where he is under the care of 12 veterinarians and biologists.

No date has been set for Yuji’s transfer to a habitat shared by 12 other adult patas monkeys and three other infants. That will depend on when he is weaned from a milk-only diet and starts an adult diet complete with fruits and vegetables, said veterinarian Iván Reynoso Ruiz, head of the primate section at the Guadalajara Zoo. That could happen when Yuji is around 6 months old, he said.

Just hours after giving birth on March 3, Kamaria began exhibiting irregular behavior. She struggled to hold her firstborn correctly, leaving the infant unable to secure a grip on its mother.

After noticing a problem, keepers separated the mother from her newborn, who weighed just 443 grams (less than a pound) and required immediate placement in an incubator at CIMBA to stabilize his temperature and safeguard his health, Reynoso Ruiz said.

This was the start of the infant's assisted rearing, a process often used by zoos to protect the health and development of at-risk offspring. A caregiver named him Yuji after a popular Japanese manga character.

During his first few weeks, Yuji was under round-the-clock supervision and was bottle-fed fortified milk.

From the start, Yuji was given a stuffed animal for comfort. Reynoso Ruiz explained that the toy fulfills the role of a mother by serving as his primary source of security. To maintain hygiene, staff rotate the original stuffed dog with two other toys — a bear and a monkey — to ensure he always has a clean companion.

To stimulate his development, caregivers outfitted Yuji’s crate with a small hammock and ropes. As he began gaining weight and sleeping for longer intervals, his team adjusted his feeding schedule. Yuji now receives the first of his four daily bottles at 7:00 a.m.

While the stories of Punch and Yuji have been popular on social media, some animal rights advocates oppose the practice of assisted rearing.

Diana Valencia, an animal rights activist, argues that there is no substitute for a natural habitat, and that animals “have the right to be born, grow, develop, and die where they belong.”

Responding to these criticisms, the Guadalajara Zoo’s primate expert emphasized that modern zoos provide a unique opportunity to protect species from global threats. He said the intervention was a matter of life or death, and that Yuji likely would have perished in the wild without a “second chance” at survival.


Trump's Triumphal Arch Gets Official Name

White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
TT

Trump's Triumphal Arch Gets Official Name

White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP
White House Press Secretary Karoline Leavitt shows off an artist's rendering of President Donald Trump's planned Triumphal Arch. Brendan SMIALOWSKI / AFP

It's been dubbed the "Arc de Trump." But now President Donald Trump's latest building project has an official name -- the "United States Triumphal Arch."

White House Press Secretary Karoline Leavitt revealed the formal title on Wednesday, saying the giant structure was being built to mark the 250th anniversary of US independence, AFP reported.

"In honor of this historic occasion, President Trump and the Department of Interior will submit plans for the United States Triumphal Arch," Leavitt told reporters.

Showing off a picture that she initially held upside down, Leavitt said the "monumental" arch would stand 250 feet (76.2 meters) tall "in honor of 250 years."

Its colossal height, including a huge golden Lady Liberty statue on top, means it will dwarf perhaps its most famous predecessor, the Arc de Triomphe in Paris, which stands at 164 feet.

In fact it is set to be the largest structure of its kind in the world, pipping Mexico City's Monument to the Revolution and knocking Pyongyang's Arch of Triumph to third place.

Plans for the arch were first revealed in October when AFP journalists spotted a model on Trump's desk in the Oval Office, after which it was quickly dubbed the "Arc de Trump" by US media.

Trump revealed the first full renderings for the structure last Friday.

The arch is one of several architectural projects -- including the construction of a gigantic White House ballroom and renovations to the Kennedy Center for the Performing Arts -- that Trump has undertaken to leave a mark on Washington in his second term.

Critics say the gold-accented arch, which will tower over the 99-foot-tall Lincoln Memorial, is a monument to the 79-year-old Trump's vanity.

The arch will partly be funded by US taxpayers, getting $2 million in special funds from the US National Endowment for the Humanities, with up to $13 million in funds to match any donations, ABC News reported.

But Leavitt said it was aimed at celebrating US national pride.

"Long after everyone in this room is gone, our children and grandchildren will remain inspired by this national monument," she told reporters.


Much-hyped Alzheimer's Drugs Do Not Help Patients, Review Finds

New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
TT

Much-hyped Alzheimer's Drugs Do Not Help Patients, Review Finds

New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File
New research has cast doubt on Alzheimer's drugs once hailed as a gamechanger. ALAIN JOCARD / AFP/File

Drugs once hailed as a breakthrough in the fight against Alzheimer's disease do not meaningfully help patients, a major review found Thursday, however some experts criticized the research.

The review by the Cochrane organization -- which is considered the gold standard for analyzing existing evidence -- looked at drugs that target a plaque called amyloids which builds up in the brains of Alzheimer's patients.

Researchers have long sought a way to eliminate this plaque, believing it could be the cause of the most common form of dementia which affects millions of elderly people every year, said AFP.

After decades of costly yet unsuccessful research, two anti-amyloid drugs called lecanemab and donanemab were initially hailed as gamechangers that finally offered a way to slow the progress of the debilitating disease.

Both drugs were approved by the United States and European Union over the last few years.

However concerns about their effectiveness, cost and side effects including an increased risk of brain swelling and bleeding have since prompted caution. State-run health services in the UK and France have refused to cover the drugs.

The new Cochrane review combined data from 17 clinical trials that included a total of more than 20,000 people with mild cognitive impairment or early dementia.

The trials, which took place over roughly 18 months, studied seven different anti-amyloid drugs.

Only one of the trials examined donanemab -- sold under the name Kisunla by US pharma giant Eli Lilly -- while one studied lecanemab, sold as Leqembi by Biogen and Eisai.

While early trials suggested these drugs made a statistically significant difference, this did not translate into "something clinically meaningful for patients," lead study author Francesco Nonino of Italy's IRCCS institute told a press conference.

Brain scans showed that the drugs successfully removed amyloids, the researchers emphasized.

This means "the idea that removing amyloids will benefit patients was refuted by our results," said study co-author Edo Richard of Radboud University Medical Center in the Netherlands.

- 'Not delivering on promise' -

Richard, who has previously expressed skepticism about anti-amyloid drugs, said he hopes efforts targeting other mechanisms that potentially cause Alzheimer's lead to more effective drugs in the future.

British biologist John Hardy, who first developed the amyloid hypothesis in the 1990s, criticized the review for lumping together data about lecanemab and donanemab along with drugs that are known to be ineffective, therefore dragging down the overall average.

"This is a silly paper which should not have been published," Hardy told AFP, disclosing that he has consulted for Eli Lilly, Biogen and Eisai.

In response to such questions, Richard said that while the drugs included in the study may work in different ways, they all have the same target: amyloid beta proteins.

Australian neuroscientist Bryce Vissel, who was not involved in the research, said it "does not prove amyloid has no role in Alzheimer's, and it does not rule out future amyloid-directed therapies that may yet help patients".

"But it does show that the current generation of anti-amyloid drugs is not delivering the promise that has surrounded it."